Minimally Invasive Biopsy Techniques Market Assessment, By Product Offered [Tests, Kits & Consumables, Instruments], By Technique [Liquid Biopsy, Optical Biopsy, Brush Biopsy, Pigmented Lesion Assays, Others], By Circulating Biomarker [Circulating Tumor Cells (CTCs), Cell Free DNA (cfDNA), Circulating Tumor DNA (ctDNA), Extracellular Vesicles, Others], By Application [Clinical, Therapeutic], By End-user [Hospitals & Clinics, Academic & Research Institutions, Ambulatory Care Centres], By Region, Opportunities and Forecast, 2016-2030F

Minimally Invasive Biopsy Techniques Market size was valued at USD 3.89 billion in 2022 which is expected to reach USD 6.93 billion in 2030 with a CAGR of 7.49% for the forecast period between 2023 and 2030.

Home>Industry Reports>Minimally Invasive Biopsy Techniques Market Assessment, Opportunities and Forecast, 2016-2030F

Global Minimally Invasive Biopsy Techniques Market size was valued at USD 3.89 billion in 2022 which is expected to reach USD 6.93 billion in 2030 with a CAGR of 7.49% for the forecast period between 2023 and 2030. Significant growth in the market is driven by several factors such as the increasing prevalence of cancer worldwide and is marked by notable advancements. The development of imaging-guided biopsy techniques, such as ultrasound-guided and MRI-guided biopsies, has enhanced the precision and accuracy of tissue sampling. These techniques allow for real-time visualization of the biopsy site, enabling physicians to target specific lesions and obtain high-quality samples. Additionally, the integration of robotics and artificial intelligence (AI) has further refined the biopsy process, enhanced procedural efficiency, and reduced human error. Furthermore, there have been notable developments in the field of liquid biopsy, which involves the analysis of circulating tumor cells, cell-free DNA, or other biomarkers in the blood. 

For example, Roche launched the FoundationOne®Liquid CDx test, a comprehensive liquid biopsy assay. It employs next-generation sequencing to detect multiple genetic alterations in ctDNA extracted from blood samples. The test is designed to identify genomic alterations in solid tumors, aiding in the selection of targeted therapies and monitoring treatment response.

Minimally invasive biopsy techniques refer to procedures that enable the extraction of tissue samples for diagnostic purposes with minimal damage to surrounding tissues and reduced patient discomfort. Minimally invasive biopsy techniques offer a less invasive alternative to traditional open suragical biopsies, making them more appealing to patients and physicians.

Increase Demand for Early and Accurate Diagnosis 

Early and accurate diagnosis is crucial for successful treatment outcomes in various medical conditions, including cancer. Minimally invasive biopsy techniques offer a less invasive and safer alternative to traditional biopsy techniques, making it a preferred choice for patients and healthcare providers. By detecting the presence of cancer cells at an early stage, the minimally invasive biopsy technique can help initiate timely and appropriate treatment, which can significantly improve patient outcomes. Therefore, increasing awareness among patients and healthcare providers about the benefits of early and accurate diagnosis through minimally invasive biopsy techniques can lead to a rise in demand for these techniques in the Global Minimally Invasive Biopsy Technique Market. Additionally, research and development to improve the accuracy and effectiveness of these techniques can further drive demand and market growth.

Technological Advancements

The Global Minimally Invasive Biopsy Techniques Market has seen significant technological advancements in recent years. One of the most notable developments has been the introduction of robotic-assisted biopsy systems that enable more accurate and less invasive procedures. Additionally, the development of advanced imaging technologies, such as ultrasound and magnetic resonance imaging (MRI), has improved the accuracy of biopsies and reduced the need for more invasive procedures. Other technological advancements, such as the use of disposable biopsy needles and the development of real-time image guidance systems, have also improved the safety and efficiency of minimally invasive biopsies. These technological advancements are expected to continue to drive growth in the market in the coming years.

Liquid Biopsy Segment Leads the Market 

Tissue biopsies are the gold standard for diagnosing cancer and profiling tumours. Despite this, biopsy procedures have been linked to a number of limitations, prompting a demand for less intrusive and more precise alternatives. Liquid biopsies are a promising contender for determining the prognosis and diagnosis of cancer in patients. Because of the large number of analytes flowing in the bloodstream that may be employed for liquid biopsy testing, it is a promising tool for the clinical care of oncological patients. Several companies focus on the launch of new liquid biopsy products in line with the same.

For example, BillionToOne, a molecular diagnostics company, launched a range of Oncology liquid biopsy products Northstar Response and Northstar Select in July 2022. Northstar Response offers a tissue-independent therapy response monitoring test, whereas Northstar Select is a thorough pan-cancer somatic mutation screening panel. Both items are now accessible for usage in research at a few prestigious academic cancer centres. 

Cell Free DNA (cfDNA) Segment Dominates

The cell-free DNA segment is set to dominate the global market for minimally invasive biopsy procedures. cfDNA is the fragmented DNA delivered into the circulation by cells dying naturally or as a result of illnesses such as cancer. Several reasons contribute to this segment's dominance. For a start, cfDNA analysis provides an alternative to standard tissue biopsies, removing the necessity for invasive surgeries and decreasing patient suffering. Secondly, cfDNA analysis allows for real-time monitoring of disease progression, treatment response, and detection of genetic abnormalities, making it a valuable tool for personalized medicine. Furthermore, advancements in technology, such as next-generation sequencing (NGS) and digital PCR, have improved the sensitivity and accuracy of cfDNA analysis, further driving its adoption and market dominance. The widespread applicability and benefits of cfDNA analysis position it as a leading segment in the global minimally invasive biopsy techniques market.

Government Initiatives

In order to increase political commitment to cancer prevention and control on a worldwide scale, WHO and IARC have worked together with other UN organizations. In addition to working with other UN organisations, such as the International Atomic Energy Agency, to track cancer prevalence (as part of the Global Initiative on Cancer Registries' activities), it aims to reach out to nations where data is scarce by conducting research on the causes of human cancer and the mechanisms of carcinogenesis.

Additionally, it focuses on identifying the "best buys" and other high-priority, cost-effective cancer prevention and control measures, such as minimally invasive biopsy techniques, and it also offers guidelines and standards to guide the creation and implementation of programmes for cancer prevention, early detection, screening, treatment, palliative care, and survivorship care in both adults and children. The effort also include raising awareness about the use of minimally invasive biopsy methods to improve access to cancer therapies by supporting regional and governmental health systems.

Impact of COVID-19

The market for minimally invasive biopsy techniques has been significantly impacted by the COVID-19 Pandemic which disrupted the global supply chain of medical devices and equipment, resulting in a decrease in the availability of minimally invasive biopsy devices. The delay or cancellation of elective procedures has led to a decrease in demand for minimally invasive biopsy procedures. Additionally, the shift towards telemedicine and virtual consultations has also impacted the market. However, the pandemic has also increased the demand for diagnostic testing, including minimally invasive biopsies, to diagnose and monitor COVID-19-related complications.

Impact of Russia-Ukraine War

The Russia-Ukraine war had a limited impact on the global minimally invasive biopsy techniques market. While Ukraine is a significant manufacturer of medical devices, including minimally invasive biopsy devices, the global market has not been heavily affected. The war has disrupted the supply chain of medical devices and equipment in Ukraine, leading to a decrease in the availability of these devices in the region. However, the impact on the global market has been minimal as other countries continue to manufacture and supply these devices. It is worth noting that the ongoing conflict has also led to a decrease in demand for medical procedures in Ukraine, including minimally invasive biopsies, due to the strain on the healthcare system and limited access to medical facilities in conflict-affected areas. 

Global Minimally Invasive Biopsy Techniques Market: Report Scope

Global Minimally Invasive Biopsy Techniques Market Assessment, Opportunities and Forecast, 2016-2030F”, is a comprehensive report by Markets & Data, providing in-depth analysis and qualitative & quantitative assessment of the current state of the minimally invasive biopsy techniques globally, industry dynamics and challenges. The report includes market size, segmental shares, growth trends, COVID-19 and Russia-Ukraine war impact, opportunities and forecast between 2023 and 2030. Additionally, the report profiles the leading players in the industry mentioning their respective market share, business model, competitive intelligence, etc.

 

Report Attribute

Details

Base Year of the Analysis

2022

Historical Period

2016-2021

Forecast Period

2023-2030

Projected Growth Rate

CAGR of 7.49% between 2023 and 2030

Revenue forecast in 2030

USD 6.93 billion

Units

Revenue in USD billion

Segments Covered

Product Offered, Technique, Circulating Biomarker, Application, End-user

Regions Covered

North America, Europe, South America, Asia Pacific, Middle East, and Africa

 

Key Companies Profiled

Thermo Fisher Scientific, Inc., F. Hoffmann-La Roche AG, QIAGEN NV, Guardant Health, Inc., Veracyte, Inc., Myriad Genetics, Inc., Biocept, Inc., NeoGenomics Laboratories, Inc., Adaptive Biotechnologies Corporation, DermTech, Inc.

Customization Scope

15% free report customization with purchase

Pricing and Purchase Options

Avail the customized purchase options to fulfil your precise research needs

Delivery Format

PDF and Excel through email (subject to the license purchased)

In this report, Global Minimally Invasive Biopsy Techniques have been segmented into following categories:

1.       By Product Offered

1.1.   Tests

1.2.    Kits & Consumables

1.3.    Instruments

2.        By Technique

2.1.    Liquid Biopsy

2.2.    Optical Biopsy

2.3.    Brush Biopsy

2.4.    Pigmented Lesion Assays

2.5.    Others

3.       By Circulating Biomarker

3.1.    Circulating Tumor Cells (CTCs)

3.2.    Cell Free DNA (cfDNA)

3.3.    Circulating Tumor DNA (ctDNA)

3.4.    Extracellular Vesicles

3.5.    Others

4.        By Application

4.1.   Clinical

4.1.1.Treatment Monitoring

4.1.2.Prognosis & Recurrence Monitoring

4.1.3.Treatment Selection

4.1.4.Others

4.2.    Therapeutic

4.2.1.Lung Cancer

4.2.2.Breast Cancer

4.2.3.Prostate Cancer

4.2.4.Colorectal Cancer

4.2.5.Others

5.      By End-user

5.1.    Hospitals & Clinics

5.2.    Academic & Research Institutions

5.3.    Ambulatory Care Centers

6.        By Region

6.1.    North America

6.2.    Europe

6.3.    South America

6.4.    Asia-Pacific

6.5.    Middle East & Africa

Key Player Landscape and Outlook

Multiple prominent manufacturers are fighting for market share in the highly competitive market for minimally invasive biopsy procedures. The companies offer a wide range of minimally invasive biopsy devices and compete based on product quality, innovation, and pricing. In recent years, there has been a significant focus on product development and innovation, with companies investing in research and development to develop new and advanced minimally invasive biopsy devices. The market is also characterized by strategic collaborations, partnerships, and mergers and acquisitions, with companies seeking to expand their product portfolios and geographic reach. 

For instance, Biocept is a prominent commercial supplier of testing services that allow doctors to discover and track cancer biomarkers in cerebrospinal fluid samples. Biocept's test menu, via CNSideTM, emphasises cancer biomarkers that are clinically actionable according to clinical treatment criteria established by the NCCN® (National Comprehensive Cancer Network®).

Key Players Operating in Global Minimally Invasive Biopsy Techniques

·         Thermo Fisher Scientific, Inc.

·         F. Hoffmann-La Roche AG

·         QIAGEN NV

·         Guardant Health, Inc.

·         Veracyte, Inc.

·         Myriad Genetics, Inc.

·         Biocept, Inc.

·         NeoGenomics Laboratories, Inc.

·         Adaptive Biotechnologies Corporation

·         DermTech, Inc.

If you can't find what you're searching for or have any custom requirements for Global Minimally Invasive Biopsy Techniques Market, you may approach our team at info@marketsandata.com

Table of Contents

1.       Research Methodology

2.       Project Scope & Definitions

3.       Impact of COVID-19

4.       Impact of Russia-Ukraine War

5.       Executive Summary

6.       Global Minimally Invasive Biopsy Techniques Market Outlook, 2016-2030F

6.1.    Market Size & Forecast

6.1.1.By Value

6.2.    By Product Offered

6.2.1.       Tests

6.2.2.Kits & Consumables

6.2.3.Instruments

6.3.     By Technique

6.3.1.Liquid Biopsy

6.3.2.Optical Biopsy

6.3.3.Brush Biopsy

6.3.4.Pigmented Lesion Assays

6.3.5.Others

6.4.    By Circulating Biomarker

6.4.1.Circulating Tumor Cells (CTCs)

6.4.2.Cell Free DNA (cfDNA)

6.4.3.Circulating Tumor DNA (ctDNA)

6.4.4.Extracellular Vesicles

6.4.5.Others

6.5.     By Application

6.5.1.       Clinical

6.5.1.1.              Treatment Monitoring

6.5.1.2.              Prognosis & Recurrence Monitoring

6.5.1.3.              Treatment Selection

6.5.1.4.              Others

6.5.2.Therapeutic

6.5.2.1.              Lung Cancer

6.5.2.2.              Breast Cancer

6.5.2.3.              Prostate Cancer

6.5.2.4.              Colorectal Cancer

6.5.2.5.              Others

6.6.   By End-user

6.6.1.Hospitals & Clinics

6.6.2.Academic & Research Institutions

6.6.3.Ambulatory Care Centers

6.7.     By Region

6.7.1.North America

6.7.2.Europe

6.7.3.South America

6.7.4.Asia-Pacific

6.7.5.Middle East & Africa

6.8.     By Company Market Share (%), 2022

7.       Global Minimally Invasive Biopsy Techniques Market Outlook, By Region, 2016-2030F

7.1.   North America*

7.1.1. By Product Offered

7.1.1.1.             Tests

7.1.1.2.              Kits & Consumables

7.1.1.3.              Instruments

7.1.2. By Technique

7.1.2.1.              Liquid Biopsy

7.1.2.2.              Optical Biopsy

7.1.2.3.              Brush Biopsy

7.1.2.4.              Pigmented Lesion Assays

7.1.2.5.              Others

7.1.3.By Circulating Biomarker

7.1.3.1.              Circulating Tumor Cells (CTCs)

7.1.3.2.              Cell Free DNA (cfDNA)

7.1.3.3.              Circulating Tumor DNA (ctDNA)

7.1.3.4.              Extracellular Vesicles

7.1.3.5.              Others

7.1.4. By Application

7.1.4.1.             Clinical

7.1.4.1.1.                    Treatment Monitoring

7.1.4.1.2.                    Prognosis & Recurrence Monitoring

7.1.4.1.3.                    Treatment Selection

7.1.4.1.4.                    Others

7.1.4.2.              Therapeutic

7.1.4.2.1.                    Lung Cancer

7.1.4.2.2.                    Breast Cancer

7.1.4.2.3.                    Prostate Cancer

7.1.4.2.4.                    Colorectal Cancer

7.1.4.2.5.                    Others

7.1.5.       By End-user

7.1.5.1.              Hospitals & Clinics

7.1.5.2.              Academic & Research Institutions

7.1.5.3.              Ambulatory Care Centers

7.1.6.United States*

7.1.6.1.              By Product Offered

7.1.6.1.1.                   Tests

7.1.6.1.2.                    Kits & Consumables

7.1.6.1.3.                    Instruments

7.1.6.2.               By Technique

7.1.6.2.1.                    Liquid Biopsy

7.1.6.2.2.                    Optical Biopsy

7.1.6.2.3.                    Brush Biopsy

7.1.6.2.4.                    Pigmented Lesion Assays

7.1.6.2.5.                    Others

7.1.6.3.              By Circulating Biomarker

7.1.6.3.1.                    Circulating Tumor Cells (CTCs)

7.1.6.3.2.                    Cell Free DNA (cfDNA)

7.1.6.3.3.                    Circulating Tumor DNA (ctDNA)

7.1.6.3.4.                    Extracellular Vesicles

7.1.6.3.5.                    Others

7.1.6.4.               By Application

7.1.6.4.1.                   Clinical

7.1.6.4.1.1.   Treatment Monitoring

7.1.6.4.1.2.   Prognosis & Recurrence Monitoring

7.1.6.4.1.3.   Treatment Selection

7.1.6.4.1.4.   Others

7.1.6.4.2.                    Therapeutic

7.1.6.4.2.1.   Lung Cancer

7.1.6.4.2.2.   Breast Cancer

7.1.6.4.2.3.   Prostate Cancer

7.1.6.4.2.4.   Colorectal Cancer

7.1.6.4.2.5.   Others

7.1.6.5.             By End-user

7.1.6.5.1.                    Hospitals & Clinics

7.1.6.5.2.                    Academic & Research Institutions

7.1.6.5.3.                    Ambulatory Care Centers

7.1.7.Canada

7.1.8.Mexico

*All segments will be provided for all regions and countries covered

7.2.   Europe

7.2.1.Germany

7.2.2.France

7.2.3.Italy

7.2.4.United Kingdom

7.2.5.Russia

7.2.6.Netherlands

7.2.7.Spain

7.2.8.Turkey

7.2.9.Poland

7.3.   South America

7.3.1.Brazil

7.3.2.Argentina

7.4.   Asia-Pacific

7.4.1.India

7.4.2.China

7.4.3.Japan

7.4.4.Australia

7.4.5.Vietnam

7.4.6.South Korea

7.4.7.Indonesia

7.4.8.Philippines

7.5.   Middle East & Africa

7.5.1.Saudi Arabia

7.5.2.UAE

7.5.3.South Africa

8.       Market Mapping, 2022

8.1.    By Product Offered

8.2.    By Technique 

8.3.    By Circulating Biomarker

8.4.    By Application

8.5.   By End-user

8.6.   By Region

9.       Macro Environment and Industry Structure

9.1.    Supply Demand Analysis

9.2.    Import Export Analysis

9.3.    Supply/Value Chain Analysis

9.4.    PESTEL Analysis

9.4.1.Political Factors

9.4.2.Economic System

9.4.3.Social Implications

9.4.4.Technological Advancements

9.4.5.Environmental Impacts

9.4.6.Legal Compliances and Regulatory Policies (Statutory Bodies Included)

9.5.    Porter’s Five Forces Analysis

9.5.1.Supplier Power

9.5.2.Buyer Power

9.5.3.Substitution Threat

9.5.4.Threat from New Entrant

9.5.5.Competitive Rivalry

10.   Market Dynamics

10.1.                     Growth Drivers

10.2.                     Growth Inhibitors (Challenges, Restraints)

11.   Key Players Landscape

11.1.                     Competition Matrix of Top Five Market Leaders

11.2.                     Market Revenue Analysis of Top Five Market Leaders (in %, 2022)

11.3.                     Mergers and Acquisitions/Joint Ventures (If Applicable)

11.4.                     SWOT Analysis (For Five Market Players)

11.5.                     Patent Analysis (If Applicable)

12.   Pricing Analysis

13.   Case Studies

14.   Key Players Outlook

14.1.                     Thermo Fisher Scientific, Inc.

14.1.1.    Company Details

14.1.2.    Key Management Personnel

14.1.3.    Products & Services

14.1.4.    Key Market Focus & Geographical Presence

14.1.5.    Financials (As Reported)

14.1.6.    Recent Developments

14.2.                     F. Hoffmann-La Roche AG

14.3.                     QIAGEN NV

14.4.                     Guardant Health, Inc.

14.5.                     Veracyte, Inc.

14.6.                     Myriad Genetics, Inc.

14.7.                     Biocept, Inc.

14.8.                     NeoGenomics Laboratories, Inc.

14.9.                     Adaptive Biotechnologies Corporation

14.10.                 DermTech, Inc.

*Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work

15.   Strategic Recommendations

About Us & Disclaimer

List of Figure-Global Minimally Invasive Biopsy Techniques Market

Figure 1. Global Minimally Invasive Biopsy Techniques Market, By Value, In USD Billion, 2016-2030F

Figure 2. Global Minimally Invasive Biopsy Techniques Market Share, By Product Offered, In USD Billion, 2016-2030F

Figure 3. Global Minimally Invasive Biopsy Techniques Market Share, By Technique, In USD Billion, 2016-2030F

Figure 4. Global Minimally Invasive Biopsy Techniques Market Share, By Circulating Biomarker, In USD Billion, 2016-2030F

Figure 5. Global Minimally Invasive Biopsy Techniques Market Share, By Application, In USD Billion, 2016-2030F

Figure 6. Global Minimally Invasive Biopsy Techniques Market Share, By End-user, In USD Billion, 2016-2030F

Figure 7. Global Minimally Invasive Biopsy Techniques Market Share, By Region, In USD Billion, 2016-2030F

Figure 8. North America Minimally Invasive Biopsy Techniques Market, By Value, In USD Billion, 2016-2030F

Figure 9. North America Minimally Invasive Biopsy Techniques Market Share, By Product Offered, In USD Billion, 2016-2030F

Figure 10. North America Minimally Invasive Biopsy Techniques Market Share, By Technique, In USD Billion, 2016-2030F

Figure 11. North America Minimally Invasive Biopsy Techniques Market Share, By Circulating Biomarker, In USD Billion, 2016-2030F

Figure 12. North America Minimally Invasive Biopsy Techniques Market Share, By Application, In USD Billion, 2016-2030F

Figure 13. North America Minimally Invasive Biopsy Techniques Market Share, By End-user, In USD Billion, 2016-2030F

Figure 14. North America Minimally Invasive Biopsy Techniques Market Share, By Country, In USD Billion, 2016-2030F

Figure 15. United States Minimally Invasive Biopsy Techniques Market, By Value, In USD Billion, 2016-2030F

Figure 16. United States Minimally Invasive Biopsy Techniques Market Share, By Product Offered, In USD Billion, 2016-2030F

Figure 17. United States Minimally Invasive Biopsy Techniques Market Share, By Technique, In USD Billion, 2016-2030F

Figure 18. United States Minimally Invasive Biopsy Techniques Market Share, By Circulating Biomarker, In USD Billion, 2016-2030F

Figure 19. United States Minimally Invasive Biopsy Techniques Market Share, By Application, In USD Billion, 2016-2030F

Figure 20. United States Minimally Invasive Biopsy Techniques Market Share, By End-user, In USD Billion, 2016-2030F

Figure 21. Canada Minimally Invasive Biopsy Techniques Market, By Value, In USD Billion, 2016-2030F

Figure 22. Canada Minimally Invasive Biopsy Techniques Market Share, By Product Offered, In USD Billion, 2016-2030F

Figure 23. Canada Minimally Invasive Biopsy Techniques Market Share, By Technique, In USD Billion, 2016-2030F

Figure 24. Canada Minimally Invasive Biopsy Techniques Market Share, By Circulating Biomarker, In USD Billion, 2016-2030F

Figure 25. Canada Minimally Invasive Biopsy Techniques Market Share, By Application, In USD Billion, 2016-2030F

Figure 26. Canada Minimally Invasive Biopsy Techniques Market Share, By End-user, In USD Billion, 2016-2030F

Figure 27. Mexico Minimally Invasive Biopsy Techniques Market, By Value, In USD Billion, 2016-2030F

Figure 28. Mexico Minimally Invasive Biopsy Techniques Market Share, By Product Offered, In USD Billion, 2016-2030F

Figure 29. Mexico Minimally Invasive Biopsy Techniques Market Share, By Technique, In USD Billion, 2016-2030F

Figure 30. Mexico Minimally Invasive Biopsy Techniques Market Share, By Circulating Biomarker, In USD Billion, 2016-2030F

Figure 31. Mexico Minimally Invasive Biopsy Techniques Market Share, By Application, In USD Billion, 2016-2030F

Figure 32. Mexico Minimally Invasive Biopsy Techniques Market Share, By End-user, In USD Billion, 2016-2030F

Figure 33. Europe Minimally Invasive Biopsy Techniques Market, By Value, In USD Billion, 2016-2030F

Figure 34. Europe Minimally Invasive Biopsy Techniques Market Share, By Product Offered, In USD Billion, 2016-2030F

Figure 35. Europe Minimally Invasive Biopsy Techniques Market Share, By Technique, In USD Billion, 2016-2030F

Figure 36. Europe Minimally Invasive Biopsy Techniques Market Share, By Circulating Biomarker, In USD Billion, 2016-2030F

Figure 37. Europe Minimally Invasive Biopsy Techniques Market Share, By Application, In USD Billion, 2016-2030F

Figure 38. Europe Minimally Invasive Biopsy Techniques Market Share, By End-user, In USD Billion, 2016-2030F

Figure 39. Europe Minimally Invasive Biopsy Techniques Market Share, By Country, In USD Billion, 2016-2030F

Figure 40. Germany Minimally Invasive Biopsy Techniques Market, By Value, In USD Billion, 2016-2030F

Figure 41. Germany Minimally Invasive Biopsy Techniques Market Share, By Product Offered, In USD Billion, 2016-2030F

Figure 42. Germany Minimally Invasive Biopsy Techniques Market Share, By Technique, In USD Billion, 2016-2030F

Figure 43. Germany Minimally Invasive Biopsy Techniques Market Share, By Circulating Biomarker, In USD Billion, 2016-2030F

Figure 44. Germany Minimally Invasive Biopsy Techniques Market Share, By Application, In USD Billion, 2016-2030F

Figure 45. Germany Minimally Invasive Biopsy Techniques Market Share, By End-user, In USD Billion, 2016-2030F

Figure 46. France Minimally Invasive Biopsy Techniques Market, By Value, In USD Billion, 2016-2030F

Figure 47. France Minimally Invasive Biopsy Techniques Market Share, By Product Offered, In USD Billion, 2016-2030F

Figure 48. France Minimally Invasive Biopsy Techniques Market Share, By Technique, In USD Billion, 2016-2030F

Figure 49. France Minimally Invasive Biopsy Techniques Market Share, By Circulating Biomarker, In USD Billion, 2016-2030F

Figure 50. France Minimally Invasive Biopsy Techniques Market Share, By Application, In USD Billion, 2016-2030F

Figure 51. France Minimally Invasive Biopsy Techniques Market Share, By End-user, In USD Billion, 2016-2030F

Figure 52. Italy Minimally Invasive Biopsy Techniques Market, By Value, In USD Billion, 2016-2030F

Figure 53. Italy Minimally Invasive Biopsy Techniques Market Share, By Product Offered, In USD Billion, 2016-2030F

Figure 54. Italy Minimally Invasive Biopsy Techniques Market Share, By Technique, In USD Billion, 2016-2030F

Figure 55. Italy Minimally Invasive Biopsy Techniques Market Share, By Circulating Biomarker, In USD Billion, 2016-2030F

Figure 56. Italy Minimally Invasive Biopsy Techniques Market Share, By Application, In USD Billion, 2016-2030F

Figure 57. Italy Minimally Invasive Biopsy Techniques Market Share, By End-user, In USD Billion, 2016-2030F

Figure 58. United Kingdom Minimally Invasive Biopsy Techniques Market, By Value, In USD Billion, 2016-2030F

Figure 59. United Kingdom Minimally Invasive Biopsy Techniques Market Share, By Product Offered, In USD Billion, 2016-2030F

Figure 60. United Kingdom Minimally Invasive Biopsy Techniques Market Share, By Technique, In USD Billion, 2016-2030F

Figure 61. United Kingdom Minimally Invasive Biopsy Techniques Market Share, By Circulating Biomarker, In USD Billion, 2016-2030F

Figure 62. United Kingdom Minimally Invasive Biopsy Techniques Market Share, By Application, In USD Billion, 2016-2030F

Figure 63. United Kingdom Minimally Invasive Biopsy Techniques Market Share, By End-user, In USD Billion, 2016-2030F

Figure 64. Russia Minimally Invasive Biopsy Techniques Market, By Value, In USD Billion, 2016-2030F

Figure 65. Russia Minimally Invasive Biopsy Techniques Market Share, By Product Offered, In USD Billion, 2016-2030F

Figure 66. Russia Minimally Invasive Biopsy Techniques Market Share, By Technique, In USD Billion, 2016-2030F

Figure 67. Russia Minimally Invasive Biopsy Techniques Market Share, By Circulating Biomarker, In USD Billion, 2016-2030F

Figure 68. Russia Minimally Invasive Biopsy Techniques Market Share, By Application, In USD Billion, 2016-2030F

Figure 69. Russia Minimally Invasive Biopsy Techniques Market Share, By End-user, In USD Billion, 2016-2030F

Figure 70. Netherlands Minimally Invasive Biopsy Techniques Market, By Value, In USD Billion, 2016-2030F

Figure 71. Netherlands Minimally Invasive Biopsy Techniques Market Share, By Product Offered, In USD Billion, 2016-2030F

Figure 72. Netherlands Minimally Invasive Biopsy Techniques Market Share, By Technique, In USD Billion, 2016-2030F

Figure 73. Netherlands Minimally Invasive Biopsy Techniques Market Share, By Circulating Biomarker, In USD Billion, 2016-2030F

Figure 74. Netherlands Minimally Invasive Biopsy Techniques Market Share, By Application, In USD Billion, 2016-2030F

Figure 75. Netherlands Minimally Invasive Biopsy Techniques Market Share, By End-user, In USD Billion, 2016-2030F

Figure 76. Spain Minimally Invasive Biopsy Techniques Market, By Value, In USD Billion, 2016-2030F

Figure 77. Spain Minimally Invasive Biopsy Techniques Market Share, By Product Offered, In USD Billion, 2016-2030F

Figure 78. Spain Minimally Invasive Biopsy Techniques Market Share, By Technique, In USD Billion, 2016-2030F

Figure 79. Spain Minimally Invasive Biopsy Techniques Market Share, By Circulating Biomarker, In USD Billion, 2016-2030F

Figure 80. Spain Minimally Invasive Biopsy Techniques Market Share, By Application, In USD Billion, 2016-2030F

Figure 81. Spain Minimally Invasive Biopsy Techniques Market Share, By End-user, In USD Billion, 2016-2030F

Figure 82. Turkey Minimally Invasive Biopsy Techniques Market, By Value, In USD Billion, 2016-2030F

Figure 83. Turkey Minimally Invasive Biopsy Techniques Market Share, By Product Offered, In USD Billion, 2016-2030F

Figure 84. Turkey Minimally Invasive Biopsy Techniques Market Share, By Technique, In USD Billion, 2016-2030F

Figure 85. Turkey Minimally Invasive Biopsy Techniques Market Share, By Circulating Biomarker, In USD Billion, 2016-2030F

Figure 86. Turkey Minimally Invasive Biopsy Techniques Market Share, By Application, In USD Billion, 2016-2030F

Figure 87. Turkey Minimally Invasive Biopsy Techniques Market Share, By End-user, In USD Billion, 2016-2030F

Figure 88. Poland Minimally Invasive Biopsy Techniques Market, By Value, In USD Billion, 2016-2030F

Figure 89. Poland Minimally Invasive Biopsy Techniques Market Share, By Product Offered, In USD Billion, 2016-2030F

Figure 90. Poland Minimally Invasive Biopsy Techniques Market Share, By Technique, In USD Billion, 2016-2030F

Figure 91. Poland Minimally Invasive Biopsy Techniques Market Share, By Circulating Biomarker, In USD Billion, 2016-2030F

Figure 92. Poland Minimally Invasive Biopsy Techniques Market Share, By Application, In USD Billion, 2016-2030F

Figure 93. Poland Minimally Invasive Biopsy Techniques Market Share, By End-user, In USD Billion, 2016-2030F

Figure 94. South America Minimally Invasive Biopsy Techniques Market, By Value, In USD Billion, 2016-2030F

Figure 95. South America Minimally Invasive Biopsy Techniques Market Share, By Product Offered, In USD Billion, 2016-2030F

Figure 96. South America Minimally Invasive Biopsy Techniques Market Share, By Technique, In USD Billion, 2016-2030F

Figure 97. South America Minimally Invasive Biopsy Techniques Market Share, By Circulating Biomarker, In USD Billion, 2016-2030F

Figure 98. South America Minimally Invasive Biopsy Techniques Market Share, By Application, In USD Billion, 2016-2030F

Figure 99. South America Minimally Invasive Biopsy Techniques Market Share, By End-user, In USD Billion, 2016-2030F

Figure 100. South America Minimally Invasive Biopsy Techniques Market Share, By Country, In USD Billion, 2016-2030F

Figure 101. Brazil Minimally Invasive Biopsy Techniques Market, By Value, In USD Billion, 2016-2030F

Figure 102. Brazil Minimally Invasive Biopsy Techniques Market Share, By Product Offered, In USD Billion, 2016-2030F

Figure 103. Brazil Minimally Invasive Biopsy Techniques Market Share, By Technique, In USD Billion, 2016-2030F

Figure 104. Brazil Minimally Invasive Biopsy Techniques Market Share, By Circulating Biomarker, In USD Billion, 2016-2030F

Figure 105. Brazil Minimally Invasive Biopsy Techniques Market Share, By Application, In USD Billion, 2016-2030F

Figure 106. Brazil Minimally Invasive Biopsy Techniques Market Share, By End-user, In USD Billion, 2016-2030F

Figure 107. Argentina Minimally Invasive Biopsy Techniques Market, By Value, In USD Billion, 2016-2030F

Figure 108. Argentina Minimally Invasive Biopsy Techniques Market Share, By Product Offered, In USD Billion, 2016-2030F

Figure 109. Argentina Minimally Invasive Biopsy Techniques Market Share, By Technique, In USD Billion, 2016-2030F

Figure 110. Argentina Minimally Invasive Biopsy Techniques Market Share, By Circulating Biomarker, In USD Billion, 2016-2030F

Figure 111. Argentina Minimally Invasive Biopsy Techniques Market Share, By Application, In USD Billion, 2016-2030F

Figure 112. Argentina Minimally Invasive Biopsy Techniques Market Share, By End-user, In USD Billion, 2016-2030F

Figure 113. Asia-Pacific Minimally Invasive Biopsy Techniques Market, By Value, In USD Billion, 2016-2030F

Figure 114. Asia-Pacific Minimally Invasive Biopsy Techniques Market Share, By Product Offered, In USD Billion, 2016-2030F

Figure 115. Asia-Pacific Minimally Invasive Biopsy Techniques Market Share, By Technique, In USD Billion, 2016-2030F

Figure 116. Asia-Pacific Minimally Invasive Biopsy Techniques Market Share, By Circulating Biomarker, In USD Billion, 2016-2030F

Figure 117. Asia-Pacific Minimally Invasive Biopsy Techniques Market Share, By Application, In USD Billion, 2016-2030F

Figure 118. Asia- Pacific Cream Market Share, By End-user, In USD Billion, 2016-2030F

Figure 119. Asia-Pacific Minimally Invasive Biopsy Techniques Market Share, By Country, In USD Billion, 2016-2030F

Figure 120. India Minimally Invasive Biopsy Techniques Market, By Value, In USD Billion, 2016-2030F

Figure 121. India Minimally Invasive Biopsy Techniques Market Share, By Product Offered, In USD Billion, 2016-2030F

Figure 122. India Minimally Invasive Biopsy Techniques Market Share, By Technique, In USD Billion, 2016-2030F

Figure 123. India Minimally Invasive Biopsy Techniques Market Share, By Circulating Biomarker, In USD Billion, 2016-2030F

Figure 124. India Minimally Invasive Biopsy Techniques Market Share, By Application, In USD Billion, 2016-2030F

Figure 125. India Minimally Invasive Biopsy Techniques Market Share, By End-user, In USD Billion, 2016-2030F

Figure 126. China Minimally Invasive Biopsy Techniques Market, By Value, In USD Billion, 2016-2030F

Figure 127. China Minimally Invasive Biopsy Techniques Market Share, By Product Offered, In USD Billion, 2016-2030F

Figure 128. China Minimally Invasive Biopsy Techniques Market Share, By Technique, In USD Billion, 2016-2030F

Figure 129. China Minimally Invasive Biopsy Techniques Market Share, By Circulating Biomarker, In USD Billion, 2016-2030F

Figure 130. China Minimally Invasive Biopsy Techniques Market Share, By Application, In USD Billion, 2016-2030F

Figure 131. China Minimally Invasive Biopsy Techniques Market Share, By End-user, In USD Billion, 2016-2030F

Figure 132. Japan Minimally Invasive Biopsy Techniques Market, By Value, In USD Billion, 2016-2030F

Figure 133. Japan Minimally Invasive Biopsy Techniques Market Share, By Product Offered, In USD Billion, 2016-2030F

Figure 134. Japan Minimally Invasive Biopsy Techniques Market Share, By Technique, In USD Billion, 2016-2030F

Figure 135. Japan Minimally Invasive Biopsy Techniques Market Share, By Circulating Biomarker, In USD Billion, 2016-2030F

Figure 136. Japan Minimally Invasive Biopsy Techniques Market Share, By Application, In USD Billion, 2016-2030F

Figure 137. Japan Minimally Invasive Biopsy Techniques Market Share, By End-user, In USD Billion, 2016-2030F

Figure 138. Australia Minimally Invasive Biopsy Techniques Market, By Value, In USD Billion, 2016-2030F

Figure 139. Australia Minimally Invasive Biopsy Techniques Market Share, By Product Offered, In USD Billion, 2016-2030F

Figure 140. Australia Minimally Invasive Biopsy Techniques Market Share, By Technique, In USD Billion, 2016-2030F

Figure 141. Australia Minimally Invasive Biopsy Techniques Market Share, By Circulating Biomarker, In USD Billion, 2016-2030F

Figure 142. Australia Minimally Invasive Biopsy Techniques Market Share, By Application, In USD Billion, 2016-2030F

Figure 143. Australia Minimally Invasive Biopsy Techniques Market Share, By End-user, In USD Billion, 2016-2030F

Figure 144. Vietnam Minimally Invasive Biopsy Techniques Market, By Value, In USD Billion, 2016-2030F

Figure 145. Vietnam Minimally Invasive Biopsy Techniques Market Share, By Product Offered, In USD Billion, 2016-2030F

Figure 146. Vietnam Minimally Invasive Biopsy Techniques Market Share, By Technique, In USD Billion, 2016-2030F

Figure 147. Vietnam Minimally Invasive Biopsy Techniques Market Share, By Circulating Biomarker, In USD Billion, 2016-2030F

Figure 148. Vietnam Minimally Invasive Biopsy Techniques Market Share, By Application, In USD Billion, 2016-2030F

Figure 149. Vietnam Minimally Invasive Biopsy Techniques Market Share, By End-user, In USD Billion, 2016-2030F

Figure 150. South Korea Minimally Invasive Biopsy Techniques Market, By Value, In USD Billion, 2016-2030F

Figure 151. South Korea Minimally Invasive Biopsy Techniques Market Share, By Product Offered, In USD Billion, 2016-2030F

Figure 152. South Korea Minimally Invasive Biopsy Techniques Market Share, By Technique, In USD Billion, 2016-2030F

Figure 153. South Korea Minimally Invasive Biopsy Techniques Market Share, By Circulating Biomarker, In USD Billion, 2016-2030F

Figure 154. South Korea Minimally Invasive Biopsy Techniques Market Share, By Application, In USD Billion, 2016-2030F

Figure 155. South Korea Minimally Invasive Biopsy Techniques Market Share, By End-user, In USD Billion, 2016-2030F

Figure 156. Indonesia Minimally Invasive Biopsy Techniques Market, By Value, In USD Billion, 2016-2030F

Figure 157. Indonesia Minimally Invasive Biopsy Techniques Market Share, By Product Offered, In USD Billion, 2016-2030F

Figure 158. Indonesia Minimally Invasive Biopsy Techniques Market Share, By Technique, In USD Billion, 2016-2030F

Figure 159. Indonesia Minimally Invasive Biopsy Techniques Market Share, By Circulating Biomarker, In USD Billion, 2016-2030F

Figure 160. Indonesia Minimally Invasive Biopsy Techniques Market Share, By Application, In USD Billion, 2016-2030F

Figure 161. Indonesia Minimally Invasive Biopsy Techniques Market Share, By End-user, In USD Billion, 2016-2030F

Figure 162. Philippines Minimally Invasive Biopsy Techniques Market, By Value, In USD Billion, 2016-2030F

Figure 163. Philippines Minimally Invasive Biopsy Techniques Market Share, By Product Offered, In USD Billion, 2016-2030F

Figure 164. Philippines Minimally Invasive Biopsy Techniques Market Share, By Technique, In USD Billion, 2016-2030F

Figure 165. Philippines Minimally Invasive Biopsy Techniques Market Share, By Circulating Biomarker, In USD Billion, 2016-2030F

Figure 166. Philippines Minimally Invasive Biopsy Techniques Market Share, By Application, In USD Billion, 2016-2030F

Figure 167. Philippines Minimally Invasive Biopsy Techniques Market Share, By End-user, In USD Billion, 2016-2030F

Figure 168. Middle East & Africa Minimally Invasive Biopsy Techniques Market, By Value, In USD Billion, 2016-2030F

Figure 169. Middle East & Africa Minimally Invasive Biopsy Techniques Market Share, By Product Offered, In USD Billion, 2016-2030F

Figure 170. Middle East & Africa Minimally Invasive Biopsy Techniques Market Share, By Technique, In USD Billion, 2016-2030F

Figure 171. Middle East & Africa Minimally Invasive Biopsy Techniques Market Share, By Circulating Biomarker, In USD Billion, 2016-2030F

Figure 172. Middle East & Africa Minimally Invasive Biopsy Techniques Market Share, By Application, In USD Billion, 2016-2030F

Figure 173. Middle East & Africa Minimally Invasive Biopsy Techniques Market Share, By End-user, In USD Billion, 2016-2030F

Figure 174. Middle East & Africa Minimally Invasive Biopsy Techniques Market Share, By Country, In USD Billion, 2016-2030F

Figure 175. Saudi Arabia Minimally Invasive Biopsy Techniques Market, By Value, In USD Billion, 2016-2030F

Figure 176. Saudi Arabia Minimally Invasive Biopsy Techniques Market Share, By Product Offered, In USD Billion, 2016-2030F

Figure 177. Saudi Arabia Minimally Invasive Biopsy Techniques Market Share, By Technique, In USD Billion, 2016-2030F

Figure 178. Saudi Arabia Minimally Invasive Biopsy Techniques Market Share, By Circulating Biomarker, In USD Billion, 2016-2030F

Figure 179. Saudi Arabia Minimally Invasive Biopsy Techniques Market Share, By Application, In USD Billion, 2016-2030F

Figure 180. Saudi Arabia Minimally Invasive Biopsy Techniques Market Share, By End-user, In USD Billion, 2016-2030F

Figure 181. UAE Minimally Invasive Biopsy Techniques Market, By Value, In USD Billion, 2016-2030F

Figure 182. UAE Minimally Invasive Biopsy Techniques Market Share, By Product Offered, In USD Billion, 2016-2030F

Figure 183. UAE Minimally Invasive Biopsy Techniques Market Share, By Technique, In USD Billion, 2016-2030F

Figure 184. UAE Minimally Invasive Biopsy Techniques Market Share, By Circulating Biomarker, In USD Billion, 2016-2030F

Figure 185. UAE Minimally Invasive Biopsy Techniques Market Share, By Application, In USD Billion, 2016-2030F

Figure 186. UAE Minimally Invasive Biopsy Techniques Market Share, By End-user, In USD Billion, 2016-2030F

Figure 187. South Africa Minimally Invasive Biopsy Techniques Market, By Value, In USD Billion, 2016-2030F

Figure 188. South Africa Minimally Invasive Biopsy Techniques Market Share, By Product Offered, In USD Billion, 2016-2030F

Figure 189. South Africa Minimally Invasive Biopsy Techniques Market Share, By Technique, In USD Billion, 2016-2030F

Figure 190. South Africa Minimally Invasive Biopsy Techniques Market Share, By Circulating Biomarker, In USD Billion, 2016-2030F

Figure 191. South Africa Minimally Invasive Biopsy Techniques Market Share, By Application, In USD Billion, 2016-2030F

Figure 192. South Africa Minimally Invasive Biopsy Techniques Market Share, By End-user, In USD Billion, 2016-2030F

Figure 193. By Product Offered Map-Market Size (USD Billion) & Growth Rate (%), 2022

Figure 194. By Technique Map-Market Size (USD Billion) & Growth Rate (%), 2022

Figure 195. By Circulating Biomarker Map-Market Size (USD Billion) & Growth Rate (%), 2022

Figure 196. By Application Map-Market Size (USD Billion) & Growth Rate (%), 2022

Figure 197. By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2022

Figure 198. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2022

List of Table-Global Minimally Invasive Biopsy Techniques Market

Table 1. Pricing Analysis of Product Offerings from Key Players

Table 2. Competition Matrix of Top 5 Market Leaders

Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)

Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

What is the market size and growth rate of the Global Minimally Invasive Biopsy Techniques Market?

arrowup
Heart

Japan Artificial Intelligence Market Assessment, Opportunities, and Forecast, FY2017-FY2031F

Japan's Artificial Intelligence market has been witnessing notable progress. The Japan Artificial Intelligence market is estimated to achieve a value of USD 15.84 billion by the fiscal year 2031, showing substantial growth from USD 5.95 billion in FY....Read More

Published on

December 2023

3,300

Heart

Vietnam Commercial Vehicle Market Assessment, Opportunities and Forecast, 2016-2030F

Vietnam Commercial Vehicle Market size was valued at USD 3.07 billion in 2022 which is expected to reach USD 5.84 billion in 2030 with a CAGR of 8.37% for the forecast period between 2023 and 2030. ....Read More

Published on

December 2023

3,300

Heart

Japan Internet of Things Market Assessment, Opportunities and Forecast, FY2017-FY2031

Japan Internet of Things Market size is valued at USD 11.71 billion in FY2023, expected to reach USD 50.08 billion in FY2031 with a CAGR of 19.92% for the forecast period between FY2024 and FY2031.....Read More

Published on

December 2023

3,300

Heart

Japan Ready-To-Eat Food Market Assessment, Opportunities, and Forecast, FY2017-FY2031F

Japan Ready-To-Eat Food Market is expected to witness a CAGR of 4.03% during the forecast period FY2024-FY2031. The market was valued at USD 8.14 billion in FY2023 and is anticipated to reach USD 11.17 billion by FY2031.....Read More

Published on

December 2023

3,300

Purchase Options

USD ($)

arrowdown

i

3,000

i

4,500

i

5,700

i

8,200

Tired of Searching?

Looking for Customization?

Some other doubt?

Need insights from a cohort?

REACH US

    icon_Five
    17, Okhla Industrial Estate Phase 3 Rd, Okhla Phase III, Okhla Industrial Estate, New Delhi, Delhi 110020
    call_Two
    +91 11 42343567
    icon_Six
    info@marketsandata.com
icon_Seven
5741 Cleveland street, Suite 120, VA beach, VA, USA 23462
call_Three
+1 (757) 343-3258
icon_Eight
190 Middle Road, # 14-10 Fortune Centre, Singapore -188979